{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:22:50Z","timestamp":1765380170813,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-018-3168-4","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T06:02:47Z","timestamp":1548396167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-7520","authenticated-orcid":false,"given":"Anna","family":"Niezgoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Winnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Kosmalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogna","family":"Kowaliszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Krysi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Czajkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"3168_CR1","doi-asserted-by":"crossref","unstructured":"Solak B, Dikicier BS, Cosansu NC, et al. Neutrophil to lymphocyte ratio in patients with vitiligo. Postepy Dermatol Alergol. 2017;34:468\u201370.","DOI":"10.5114\/ada.2017.71114"},{"key":"3168_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5114\/pdia.2016.59507","volume":"33","author":"E Karag\u00fcn","year":"2016","unstructured":"Karag\u00fcn E, Ergin C, Baysak S, et al. The role of serum vitamin D levels in vitiligo. Postepy Dermatol Alergol. 2016;33:300\u20132.","journal-title":"Postepy Dermatol Alergol"},{"key":"3168_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","volume":"188","author":"GS Ogg","year":"1998","unstructured":"Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998;188:1203\u20138.","journal-title":"J Exp Med"},{"key":"3168_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1755-148X.2011.00878.x","volume":"24","author":"JG Boorn van den","year":"2011","unstructured":"van den Boorn JG, Melief CJ, Luiten RM. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigm Cell Melanoma R. 2011;24:673\u20139.","journal-title":"Pigm Cell Melanoma R"},{"key":"3168_CR5","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132:1869\u201376.","journal-title":"J Invest Dermatol"},{"key":"3168_CR6","doi-asserted-by":"crossref","unstructured":"Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6:223.","DOI":"10.1126\/scitranslmed.3007811"},{"key":"3168_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/jid.2014.529","volume":"135","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2015;135:1080\u20138.","journal-title":"J Invest Dermatol"},{"key":"3168_CR8","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/eji.200838189","volume":"38","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Qin H, Benveniste EN. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol. 2008;38:2325\u201336.","journal-title":"Eur J Immunol"},{"key":"3168_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","volume":"15","author":"G Iannella","year":"2016","unstructured":"Iannella G, Greco A, Didona D, et al. Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2016;15:335\u201343.","journal-title":"Autoimmun Rev"},{"key":"3168_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2133.2009.09217.x","volume":"161","author":"ZA Taher","year":"2009","unstructured":"Taher ZA, Lauzon G, Maguiness S, et al. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol. 2009;161:654\u20139.","journal-title":"Br J Dermatol"},{"key":"3168_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0014-2999(00)00870-0","volume":"410","author":"O Grip","year":"2000","unstructured":"Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol. 2000;410:83\u201392.","journal-title":"Eur J Pharmacol"},{"key":"3168_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","volume":"353","author":"RS Rosenson","year":"1999","unstructured":"Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983\u20134.","journal-title":"Lancet"},{"key":"3168_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","volume":"36","author":"DA Bassiouny","year":"2011","unstructured":"Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36:292\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"3168_CR14","first-page":"39","volume":"60","author":"PJ Kotyla","year":"2014","unstructured":"Kotyla PJ. Plejotropowe dzia\u0142anie inhibitor\u00f3w 3-hydroksy-3-metylo-glutarylo-koenzymu A (statyn). Potencja\u0142 leczniczy w uk\u0142adowych chorobach tkanki \u0142\u0105cznej. Annales Academiae Medicae Stetinensis, Rocznik Pomorskiej Akademii Medycznej w Szczecinie. 2014;60:39\u201346.","journal-title":"Annales Academiae Medicae Stetinensis, Rocznik Pomorskiej Akademii Medycznej w Szczecinie"},{"key":"3168_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12026-008-8019-z","volume":"41","author":"X Zhangm","year":"2008","unstructured":"Zhangm X, Markovic-Plese S. Statins\u2019 immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res. 2008;41:165\u201374.","journal-title":"Immunol Res"},{"key":"3168_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1096\/fj.04-2702fje","volume":"19","author":"R Ghittoni","year":"2005","unstructured":"Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 2005;19:605\u20137.","journal-title":"FASEB J"},{"key":"3168_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nri1268","volume":"4","author":"M Vicente-Manzanares","year":"2004","unstructured":"Vicente-Manzanares M, S\u00e1nchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol. 2004;4:110\u201322.","journal-title":"Nat Rev Immunol"},{"key":"3168_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.joen.2009.02.004","volume":"35","author":"SK Lin","year":"2009","unstructured":"Lin SK, Kok SH, Lee YL, et al. Simvastatin as a novel strategy to alleviate periapical lesions. J Endodontics. 2009;35:657\u201362.","journal-title":"J Endodontics"},{"key":"3168_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/dth.12143","volume":"27","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Mooneyan-Ramchurn JS, Zuo N, et al. Vitiligo nonsurgical treatment: a review of latest treatment researches. Dermatol Ther. 2014;27:298\u2013303.","journal-title":"Dermatol Ther"},{"key":"3168_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-4632.2012.05697.x","volume":"52","author":"R Wong","year":"2013","unstructured":"Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491\u20136.","journal-title":"Int J Dermatol"},{"key":"3168_CR21","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.ajpath.2012.08.023","volume":"181","author":"J Asai","year":"2012","unstructured":"Asai J, Takenaka H, Hirakawa S, et al. Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am J Pathol. 2012;181:2217\u201324.","journal-title":"Am J Pathol"},{"key":"3168_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000367851","volume":"54","author":"KG Ooi","year":"2015","unstructured":"Ooi KG, Wakefield D, Billson FA, et al. Efficacy and safety of topical atorvastatin for the treatment of dry eye associated with blepharitis: a pilot study. Ophthalmic Res. 2015;54:26\u201333.","journal-title":"Ophthalmic Res"},{"key":"3168_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/phar.1339","volume":"34","author":"S Farsaei","year":"2014","unstructured":"Farsaei S, Khalili H, Farboud ES, et al. Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial. Pharmacotherapy. 2014;34:19\u201327.","journal-title":"Pharmacotherapy"},{"key":"3168_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jobcr.2015.11.003","volume":"6","author":"HS Grover","year":"2016","unstructured":"Grover HS, Kapoor S, Singh A. Effect of topical simvastatin (1.2 mg) on gingival crevicular fluid interleukin-6, interleukin-8 and interleukin-10 levels in chronic periodontitis\u2014a clinicobiochemical study. J Oral Biol Craniofac Res. 2016;6:85\u201392.","journal-title":"J Oral Biol Craniofac Res"},{"key":"3168_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","volume":"76","author":"SG Vanderweil","year":"2017","unstructured":"Vanderweil SG, Amano S, Ko WC, et al. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017;76:150\u20131.","journal-title":"J Am Acad Dermatol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3168-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:12:46Z","timestamp":1579893166000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3168-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3168"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3168-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"11 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol has been approved by The Ethics Committee of Nicolaus Copernicus University in Toru\u0144, Ludwik Rydygier Collegium Medicum in Bydgoszcz (approval number KB 597\/2016). All study-related procedures can be performed only after obtaining written informed consent from the participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"78"}}